CatalystPit
TerminalPit ConsensusInsidersPoliticiansInstitutionsNewsScreener

SMMTSummit Therapeutics Inc.

NASDAQ · Pharmaceutical Preparations
Last close $16.91 · 2026-09-30
ABOUT
ExchangeNASDAQ
SectorHealthcare
IndustryPharmaceutical Preparations
RECENT INSIDER TRADES
  • 2026-06-12 · Zanganeh Mahkam (Co-Chief Executive Officer) · BUY
  • 2026-06-12 · DUGGAN ROBERT W (Co-Chief Executive Officer) · BUY
  • 2026-06-04 · Zanganeh Mahkam (Co-Chief Executive Officer) · BUY
  • 2026-06-04 · Soni Manmeet Singh (COO and CFO) · BUY
  • 2026-06-04 · DUGGAN ROBERT W (Co-Chief Executive Officer) · BUY
INSTITUTIONAL OWNERSHIP
Institutional holders264
Shares held156,132,367
Value$2.20B
Percent of shares outstanding19.57%
As of quarter end2026-06-30
RECENT NEWS
  • Bernstein reiterates Summit Therapeutics stock rating on trial concerns
  • AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo
  • H.C. Wainwright reiterates Summit Therapeutics stock rating as Neutral
  • Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal
  • Summit Therapeutics: Stronger Balance Sheet Helps, But It Does Not De-Risk Ivonescimab
CatalystPit
FeaturesComing soonPricingComing soonPrivacyTermsDisclaimerAffiliate TermsContact
2026 CATALYSTPIT · NOT FINANCIAL ADVICE · DELAYED FILINGS
Summit Therapeutics Inc. (SMMT) · Stock Price, Insider Trades, Institutional Holdings · CatalystPit